Thomas Dick

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6991266/publications.pdf

Version: 2024-02-01

167	9,145	44069	49909
papers	citations	48 h-index	87 g-index

177	177	177	8154
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Critical discussion on drug efflux in Mycobacterium tuberculosis. FEMS Microbiology Reviews, 2022, 46, .	8.6	29
2	Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0140021.	3.2	8
3	In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiology Spectrum, 2022, 10, e0132121.	3.0	11
4	A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0221221.	3.2	13
5	Mutational Analysis of Mycobacterial F-ATP Synthase Subunit Î´ Leads to a Potent Î´ Enzyme Inhibitor. ACS Chemical Biology, 2022, 17, 529-535.	3.4	6
6	Structureâ€“Activity Relationship of Anti-Mycobacterium abscessus Piperidine-4-carboxamides, a New Class of NBTI DNA Gyrase Inhibitors. ACS Medicinal Chemistry Letters, 2022, 13, 417-427.	2.8	2
7	Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1. Antimicrobial Agents and Chemotherapy, 2022, 66, e0001822.	3.2	4
8	Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue. Journal of Experimental Medicine, 2022, 219, .	8.5	16
9	Atomic solution structure of Mycobacterium abscessus<scp>Fâ€ATP</scp> synthase subunit Îµ and identification of <scp>Ep1MabF1</scp> as a targeted inhibitor. FEBS Journal, 2022, 289, 6308-6323.	4.7	5
10	Structural and Mechanistic Insights into Mycobacterium abscessus Aspartate Decarboxylase PanD and a Pyrazinoic Acid-Derived Inhibitor. ACS Infectious Diseases, 2022, 8, 1324-1335.	3.8	4
11	A systematic assessment of mycobacterial F₁â€ATPase subunit Îµâ€™s role in latent ATPase hydrolysis. FEBS Journal, 2021, 288, 818-836.	4.7	11
12	Amideâ€“Amine Replacement in Indole-2-carboxamides Yields Potent Mycobactericidal Agents with Improved Water Solubility. ACS Medicinal Chemistry Letters, 2021, 12, 704-712.	2.8	10
13	A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Antimycobacterial Activity. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	23
14	Mycobacterium tuberculosis PanD Structureâ€“Function Analysis and Identification of a Potent Pyrazinoic Acid-Derived Enzyme Inhibitor. ACS Chemical Biology, 2021, 16, 1030-1039.	3.4	9
15	Potency boost of a Mycobacterium tuberculosis dihydrofolate reductase inhibitor by multienzyme F ₄₂₀ H ₂ -dependent reduction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	9
16	Reinvestigation of the structure-activity relationships of isoniazid. Tuberculosis, 2021, 129, 102100.	1.9	4
17	Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0067621.	3.2	14
18	Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0097821.	3.2	13

#	Article	IF	Citations
19	A Ginger Root or Plum Model for the Tuberculosis â€œGranulomaâ€?. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 505-507.	5.6	2
20	Epetraborole Is Active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0115621.	3.2	17
21	A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0151421.	3.2	10
22	Functionalized Dioxonaphthoimidazoliums: A Redox Cycling Chemotype with Potent Bactericidal Activities against Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2021, 64, 15991-16007.	6.4	10
23	Rifabutin Is Active against Mycobacterium abscessus in Mice. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	59
24	Unique structural and mechanistic properties of mycobacterial F-ATP synthases: Implications for drug design. Progress in Biophysics and Molecular Biology, 2020, 152, 64-73.	2.9	22
25	Targeted protein degradation in antibacterial drug discovery?. Progress in Biophysics and Molecular Biology, 2020, 152, 10-14.	2.9	14
26	Overexpression, purification, enzymatic and microscopic characterization of recombinant mycobacterial F-ATP synthase. Biochemical and Biophysical Research Communications, 2020, 522, 374-380.	2.1	8
27	Indole Propionic Acid, an Unusual Antibiotic Produced by the Gut Microbiota, With Anti-inflammatory and Antioxidant Properties. Frontiers in Microbiology, 2020, 11, 575586.	3.5	49
28	Resistance against Membrane-Inserting MmpL3 Inhibitor through Upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	1
29	Single Cell Analysis of Drug Susceptibility of Mycobacterium abscessus during Macrophage Infection. Antibiotics, 2020, 9, 711.	3.7	3
30	Potency Increase of Spiroketal Analogs of Membrane Inserting Indolyl Mannich Base Antimycobacterials Is Due to Acquisition of MmpL3 Inhibition. ACS Infectious Diseases, 2020, 6, 1882-1893.	3.8	14
31	Rifabutin: A Repurposing Candidate for Mycobacterium abscessus Lung Disease. Frontiers in Microbiology, 2020, 11, 371.	3.5	7
32	Extreme Drug Tolerance of Mycobacterium abscessus â€œPersistersâ€• Frontiers in Microbiology, 2020, 11, 359.	3.5	42
33	Antituberculosis Activity of the Antimalaria Cytochrome bcc Oxidase Inhibitor SCR0911. ACS Infectious Diseases, 2020, 6, 725-737.	3.8	10
34	Reply to Vargas and Farhat: Mycobacterium tuberculosis glpK mutants in human tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3913-3914.	7.1	3
35	Rifabutin Suppresses Inducible Clarithromycin Resistance in Mycobacterium abscessus by Blocking Induction of whiB7 and erm41. Antibiotics, 2020, 9, 72.	3.7	20
36	Discovery of a Novel Mycobacterial Fâ€ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines. Angewandte Chemie, 2020, 132, 13397-13406.	2.0	4

#	Article	IF	Citations
37	Pyrazinamide triggers degradation of its target aspartate decarboxylase. Nature Communications, 2020, 11, 1661.	12.8	66
38	Discovery of a Novel Mycobacterial Fâ€ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines. Angewandte Chemie - International Edition, 2020, 59, 13295-13304.	13.8	28
39	TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drugâ€™s Uncoupler Activity. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	22
40	TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	34
41	Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	33
42	TBAJ-876 Retains Bedaquilineâ€™s Activity against Subunits c and Îµ of Mycobacterium tuberculosis F-ATP Synthase. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	37
43	Editorial: NTMâ€”The New Uber-Bugs. Frontiers in Microbiology, 2019, 10, 1299.	3.5	7
44	Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide. Trends in Pharmacological Sciences, 2019, 40, 930-940.	8.7	35
45	Disrupting coupling within mycobacterial F-ATP synthases subunit Îµ causes dysregulated energy production and cell wall biosynthesis. Scientific Reports, 2019, 9, 16759.	3.3	29
46	Thienopyrimidinone Derivatives That Inhibit Bacterial tRNA (Guanine37-N¹)-Methyltransferase (TrmD) by Restructuring the Active Site with a Tyrosine-Flipping Mechanism. Journal of Medicinal Chemistry, 2019, 62, 7788-7805.	6.4	27
47	Phase variation in Mycobacterium tuberculosis glpK produces transiently heritable drug tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19665-19674.	7.1	96
48	Repositioning rifamycins for Mycobacterium abscessus lung disease. Expert Opinion on Drug Discovery, 2019, 14, 867-878.	5.0	49
49	Bedaquiline Eliminates Bactericidal Activity of Î²-Lactams against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
50	Gut Microbiota Metabolite Indole Propionic Acid Targets Tryptophan Biosynthesis in Mycobacterium tuberculosis. MBio, 2019, 10, .	4.1	63
51	Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline. Antibiotics, 2019, 8, 261.	3.7	37
52	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 947-951.	5.6	53
53	Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	79
54	NTM drug discovery: status, gaps and the way forward. Drug Discovery Today, 2018, 23, 1502-1519.	6.4	186

#	Article	IF	Citations
55	The <scp>NMR</scp> solution structure of Mycobacterium tuberculosis Fâ€<scp>ATP</scp> synthase subunit Îµ provides new insight into energy coupling inside the rotary engine. FEBS Journal, 2018, 285, 1111-1128.	4.7	37
56	1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity. European Journal of Medicinal Chemistry, 2018, 144, 262-276.	5.5	30
57	Whole-Cell Screen of Fragment Library Identifies Gut Microbiota Metabolite Indole Propionic Acid as Antitubercular. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	49
58	Novel Acetamide Indirectly Targets Mycobacterial Transporter MmpL3 by Proton Motive Force Disruption. Frontiers in Microbiology, 2018, 9, 2960.	3.5	28
59	Structure and function of Mycobacterium-specific components of F-ATP synthase subunits Î± and Îµ. Journal of Structural Biology, 2018, 204, 420-434.	2.8	9
60	The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs. Frontiers in Microbiology, 2018, 9, 1627.	3.5	40
61	Teicoplanin â€“ Tigecycline Combination Shows Synergy Against Mycobacterium abscessus. Frontiers in Microbiology, 2018, 9, 932.	3.5	19
62	Impact of immunopathology on the antituberculous activity of pyrazinamide. Journal of Experimental Medicine, 2018, 215, 1975-1986.	8.5	29
63	Mycobacterial Cell Wall Synthesis Inhibitors Cause Lethal ATP Burst. Frontiers in Microbiology, 2018, 9, 1898.	3.5	53
64	TB drug susceptibility is more than MIC. Nature Microbiology, 2018, 3, 971-972.	13.3	6
65	Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity. Journal of Medicinal Chemistry, 2018, 61, 5733-5750.	6.4	28
66	Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	25
67	In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ACS Infectious Diseases, 2017, 3, 492-501.	3.8	33
68	Rifabutin Is Active against Mycobacterium abscessus Complex. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	119
69	The uniqueness of subunit Î± of mycobacterial F-ATP synthases: An evolutionary variant for niche adaptation. Journal of Biological Chemistry, 2017, 292, 11262-11279.	3.4	33
70	Draft Genome Sequence of Mycobacterium abscessus Bamboo. Genome Announcements, 2017, 5, .	0.8	32
71	Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structureâ€“Activity Relationships and Membrane Targeting Properties. Journal of Medicinal Chemistry, 2017, 60, 2745-2763.	6.4	68
72	Mycobacterial Caseinolytic Protease Gene Regulator ClgR Is a Substrate of Caseinolytic Protease. MSphere, 2017, 2, .	2.9	16

#	Article	IF	Citations
73	Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	29
74	Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD. ACS Infectious Diseases, 2017, 3, 807-819.	3.8	52
75	Indolylalkyltriphenylphosphonium Analogues Are Membrane-Depolarizing Mycobactericidal Agents. ACS Medicinal Chemistry Letters, 2017, 8, 1165-1170.	2.8	19
76	Draft Genome Sequence of Mycobacterium avium 11. Genome Announcements, 2017, 5, .	0.8	7
77	Missense Mutations in the Unfoldase ClpC1 of the Caseinolytic Protease Complex Are Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	31
78	Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome. Frontiers in Microbiology, 2017, 8, 746.	3.5	19
79	Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates. Frontiers in Microbiology, 2017, 8, 1539.	3.5	57
80	Boromycin Kills Mycobacterial Persisters without Detectable Resistance. Frontiers in Microbiology, 2016, 7, 199.	3.5	67
81	Mild Nutrient Starvation Triggers the Development of a Small-Cell Survival Morphotype in Mycobacteria. Frontiers in Microbiology, 2016, 7, 947.	3.5	49
82	Rel Is Required for Morphogenesis of Resting Cells in Mycobacterium smegmatis. Frontiers in Microbiology, 2016, 7, 1390.	3.5	20
83	Fragment-Based Whole Cell Screen Delivers Hits against M. tuberculosis and Non-tuberculous Mycobacteria. Frontiers in Microbiology, 2016, 7, 1392.	3.5	20
84	Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ACS Infectious Diseases, 2016, 2, 616-626.	3.8	83
85	Deletion of a unique loop in the mycobacterial Fâ€‹<scp>ATP</scp> synthase Î³ subunit sheds light on its inhibitory role in <scp>ATP</scp> hydrolysisâ€‹driven H⁺ pumping. FEBS Journal, 2016, 283, 1947-1961.	4.7	43
86	Developmental transcriptome of resting cell formation in Mycobacterium smegmatis. BMC Genomics, 2016, 17, 837.	2.8	30
87	Membrane-targeting AM-0016 kills mycobacterial persisters and shows low propensity for resistance development. Future Microbiology, 2016, 11, 643-650.	2.0	36
88	The uniqueness of subunit Î± and Î³ of mycobacterial F-ATP synthases: Evolutionary variants for niche adaptation. Biochimica Et Biophysica Acta - Bioenergetics, 2016, 1857, e90.	1.0	0
89	Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties. European Journal of Medicinal Chemistry, 2016, 123, 684-703.	5.5	30
90	Bedaquiline Targets the Îµ Subunit of Mycobacterial F-ATP Synthase. Antimicrobial Agents and Chemotherapy, 2016, 60, 6977-6979.	3.2	58

#	Article	IF	Citations
91	Eagle Effect in Nonreplicating Persister Mycobacteria. Antimicrobial Agents and Chemotherapy, 2015, 59, 7786-7789.	3.2	13
92	Antibacterial Drug Discovery: Doing It Right. Chemistry and Biology, 2015, 22, 5-6.	6.0	9
93	The new tuberculosis drug PerchlozoneÂ® shows cross-resistance with thiacetazone. International Journal of Antimicrobial Agents, 2015, 45, 430-433.	2.5	23
94	Metabolic flexibility and morphological plasticity in mycobacteria. Future Microbiology, 2015, 10, 449-452.	2.0	3
95	Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria. MBio, 2015, 6, e00253-15.	4.1	69
96	Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. Journal of Antimicrobial Chemotherapy, 2015, 70, 857-867.	3.0	129
97	Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis. PLoS ONE, 2014, 9, e105222.	2.5	23
98	Future target-based drug discovery for tuberculosis?. Tuberculosis, 2014, 94, 551-556.	1.9	43
99	Reactive dirty fragments: implications for tuberculosis drug discovery. Current Opinion in Microbiology, 2014, 21, 7-12.	5.1	28
100	Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides: A Promising Class of Antituberculosis Agents. Journal of Medicinal Chemistry, 2013, 56, 8849-8859.	6.4	85
101	In silico analyses for the discovery of tuberculosis drug targets. Journal of Antimicrobial Chemotherapy, 2013, 68, 2701-2709.	3.0	30
102	A novel <scp>F₄₂₀</scp>â€dependent antiâ€oxidant mechanism protects <scp>M</scp>ycobacterium tuberculosis against oxidative stress and bactericidal agents. Molecular Microbiology, 2013, 87, 744-755.	2.5	99
103	Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis. Science Translational Medicine, 2013, 5, 214ra168.	12.4	134
104	Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1648-1653.	3.2	133
105	para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.. Journal of Biological Chemistry, 2013, 288, 28951.	3.4	3
106	Variations of Subunit Îµ of the Mycobacterium tuberculosis F ₁ F _o ATP Synthase and a Novel Model for Mechanism of Action of the Tuberculosis Drug TMC207. Antimicrobial Agents and Chemotherapy, 2013, 57, 168-176.	3.2	64
107	para-Aminosalicylic Acid Is a Prodrug Targeting Dihydrofolate Reductase in Mycobacterium tuberculosis. Journal of Biological Chemistry, 2013, 288, 23447-23456.	3.4	158
108	Characterization of Phosphofructokinase Activity in Mycobacterium tuberculosis Reveals That a Functional Glycolytic Carbon Flow Is Necessary to Limit the Accumulation of Toxic Metabolic Intermediates under Hypoxia. PLoS ONE, 2013, 8, e56037.	2.5	46

#	Article	IF	Citations
109	Exploring the Mode of Action of Bioactive Compounds by Microfluidic Transcriptional Profiling in Mycobacteria. PLoS ONE, 2013, 8, e69191.	2.5	14
110	Heterogeneity of Mycobacterium tuberculosis strains in Makassar, Indonesia. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1441-1448.	1.2	7
111	HowMycobacterium tuberculosisgoes to sleep: the dormancy survival regulator DosR a decade later. Future Microbiology, 2012, 7, 513-518.	2.0	88
112	Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis, 2012, 92, 453-488.	1.9	193
113	Detection and treatment of subclinical tuberculosis. Tuberculosis, 2012, 92, 447-452.	1.9	33
114	A High-Throughput Screen To Identify Inhibitors of ATP Homeostasis in Non-replicating Mycobacterium tuberculosis. ACS Chemical Biology, 2012, 7, 1190-1197.	3.4	123
115	Substrate specificity of the deazaflavinâ€dependent nitroreductase from Mycobacteriumâ€ƒtuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS Journal, 2012, 279, 113-125.	4.7	70
116	Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824. Structure, 2012, 20, 101-112.	3.3	80
117	How antibacterials really work: impact on drug discovery. Future Microbiology, 2011, 6, 603-604.	2.0	18
118	Structureâ€“Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824).. Journal of Medicinal Chemistry, 2011, 54, 5639-5659.	6.4	38
119	Drug resistance among tuberculosis patients attending diagnostic and treatment centres in Makassar, Indonesia. International Journal of Tuberculosis and Lung Disease, 2011, 15, 489-495.	1.2	17
120	Vitamin B6 biosynthesis is essential for survival and virulence of Mycobacterium tuberculosis. Molecular Microbiology, 2010, 78, 980-988.	2.5	78
121	Spectrum of latent tuberculosis â€" existing tests cannot resolve the underlying phenotypes: author's reply. Nature Reviews Microbiology, 2010, 8, 242-242.	28.6	15
122	Nitrate Respiration Protects Hypoxic Mycobacterium tuberculosis Against Acid- and Reactive Nitrogen Species Stresses. PLoS ONE, 2010, 5, e13356.	2.5	91
123	A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nature Communications, 2010, 1, 57.	12.8	250
124	Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology (United Kingdom), 2010, 156, 81-87.	1.8	251
125	Lipid Droplet-associated Proteins Are Involved in the Biosynthesis and Hydrolysis of Triacylglycerol in Mycobacterium bovis Bacillus Calmette-GuÃ©rin. Journal of Biological Chemistry, 2010, 285, 21662-21670.	3.4	72
126	Tuberculosis Biology and Drug Discovery. , 2010, , 13-18.		0

#	Article	IF	Citations
127	Triacylglycerol Utilization Is Required for Regrowth of In Vitro Hypoxic Nonreplicating Mycobacterium bovis Bacillus Calmette-Guerin. Journal of Bacteriology, 2009, 191, 5037-5043.	2.2	119
128	The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Reviews Microbiology, 2009, 7, 845-855.	28.6	1,179
129	Structureâ^'Activity Relationships of Antitubercular Nitroimidazoles. 2. Determinants of Aerobic Activity and Quantitative Structureâ^'Activity Relationships. Journal of Medicinal Chemistry, 2009, 52, 1329-1344.	6.4	82
130	Peptide deformylase inhibitors of Mycobacterium tuberculosis: Synthesis, structural investigations, and biological results. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6568-6572.	2.2	37
131	Recombinase-based reporter system and antisense technology to study gene expression and essentiality in hypoxic nonreplicating mycobacteria. FEMS Microbiology Letters, 2008, 284, 68-75.	1.8	10
132	Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 ofMycobacterium tuberculosis. FEMS Microbiology Letters, 2008, 287, 128-135.	1.8	18
133	The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11945-11950.	7.1	471
134	Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2008, 62, 713-719.	3.0	92
135	Sensitive profiling of chemically diverse bioactive lipids. Journal of Lipid Research, 2007, 48, 1976-1984.	4.2	82
136	Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 431-436.	7.1	325
137	Peptide Deformylase Inhibitors as Potent Antimycobacterial Agents. Antimicrobial Agents and Chemotherapy, 2006, 50, 3665-3673.	3.2	50
138	Role for malonyl coenzyme A:acyl carrier protein transacylase (MCAT) in the growth-inhibitory effect of the calmodulin antagonist trifluoperazine in Mycobacterium bovis BCG. Journal of Antimicrobial Chemotherapy, 2004, 53, 1072-1075.	3.0	6
139	Isoniazid resistance of exponentially growingMycobacterium smegmatisbiofilm culture. FEMS Microbiology Letters, 2003, 227, 171-174.	1.8	54
140	Apparent growth phase-dependent phosphorylation of malonyl coenzyme A:acyl carrier protein transacylase (MCAT), a major fatty acid synthase II component inMycobacterium bovisBCG. FEMS Microbiology Letters, 2003, 227, 141-147.	1.8	5
141	Mycobacterium bovis BCG Response Regulator Essential for Hypoxic Dormancy. Journal of Bacteriology, 2002, 184, 6760-6767.	2.2	255
142	In vitro activity of the chelating agents nitroxoline and oxine against Mycobacterium bovis BCG. International Journal of Antimicrobial Agents, 2001, 18, 579-582.	2.5	20
143	In Vitro Activities of Mitomycin C against Growing and Hypoxic Dormant Tubercle Bacilli. Antimicrobial Agents and Chemotherapy, 2001, 45, 2403-2404.	3.2	12
144	Mycobacterium bovis BCG recADeletion Mutant Shows Increased Susceptibility to DNA-Damaging Agents but Wild-Type Survival in a Mouse Infection Model. Infection and Immunity, 2001, 69, 3562-3568.	2.2	57

#	Article	IF	Citations
145	Proteins of Mycobacterium bovis BCG Induced in the Wayne Dormancy Model. Journal of Bacteriology, 2001, 183, 2672-2676.	2.2	111
146	Plate-based dormancy culture system for Mycobacterium smegmatis and isolation of metronidazole-resistant mutants. FEMS Microbiology Letters, 2001, 200, 215-219.	1.8	0
147	Bacterial and host-derived cationic proteins bind Î±2-laminins and enhance Mycobacterium leprae attachment to human Schwann cells. Microbes and Infection, 2000, 2, 1407-1417.	1.9	40
148	Analysis of the dormancy-inducibleNarK2promoter inMycobacterium bovisBCG. FEMS Microbiology Letters, 2000, 188, 141-146.	1.8	34
149	Inducibility of the Streptomyces traRts107-Ptra Expression Cassette in Mycobacterium smegmatis. Biological Chemistry, 2000, 381, 517-9.	2.5	8
150	Up-regulation ofnarX, encoding a putative Ã¢Â€Â˜fused nitrate reductaseÃ¢Â€Â™ in anaerobic dormantMycobacterium bovisBCG. FEMS Microbiology Letters, 1999, 178, 63-69.	1.8	44
151	Upregulation of stress response genes and ABC transporters in anaerobic stationary-phase Mycobacterium smegmatis. Molecular Genetics and Genomics, 1999, 262, 677-682.	2.4	32
152	Molecular genetic characterisation of whiB3, a mycobacterial homologue of a Streptomyces sporulation factor. Research in Microbiology, 1999, 150, 295-301.	2.1	21
153	Up-regulation of narX, encoding a putative 'fused nitrate reductase' in anaerobic dormant Mycobacterium bovis BCG. FEMS Microbiology Letters, 1999, 178, 63-69.	1.8	2
154	Oxygen Depletion-Induced Dormancy in Mycobacterium bovis BCG. Journal of Bacteriology, 1999, 181, 2252-2256.	2.2	117
155	Oxygen depletion induced dormancy inMycobacterium smegmatis. FEMS Microbiology Letters, 1998, 163, 159-164.	1.8	154
156	Increased alanine dehydrogenase activity during dormancy inMycobacterium smegmatis. FEMS Microbiology Letters, 1998, 167, 7-11.	1.8	68
157	Upregulation of a histone-like protein in dormant Mycobacterium smegmatis. Molecular Genetics and Genomics, 1998, 260, 475-479.	2.4	53
158	Increased alanine dehydrogenase activity during dormancy in Mycobacterium smegmatis. FEMS Microbiology Letters, 1998, 167, 7-11.	1.8	3
159	Oxygen depletion induced dormancy in Mycobacterium smegmatis. FEMS Microbiology Letters, 1998, 163, 159-164.	1.8	3
160	Drosophila DPP2C1, a novel member of the protein phosphatase 2C (PP2C) family. Gene, 1997, 199, 139-143.	2.2	4
161	Cytoplasmic Dynein (ddlc1) Mutations Cause Morphogenetic Defects and Apoptotic Cell Death in Drosophila melanogaster. Molecular and Cellular Biology, 1996, 16, 1966-1977.	2.3	160
162	The role of a Drosophila POU homeo domain gene in the specification of neural precursor cell identity in the developing embryonic central nervous system.. Genes and Development, 1993, 7, 504-516.	5.9	66

#	Article	IF	Citations
163	Two closely linked Drosophila POU domain genes are expressed in neuroblasts and sensory elements.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7645-7649.	7.1	58
164	Chloramphenicol-induced translational activation of cat messenger RNA in vitro. Journal of Molecular Biology, 1990, 212, 661-668.	4.2	11
165	Positioning ribosomes on leader mRNA for translational activation of the message of an inducible Staphylococcus aureus cat gene. Molecular Genetics and Genomics, 1988, 214, 108-111.	2.4	18
166	Dependence of expression of an inducible Staphylococcus aureus cat gene on the translation of its leader sequence. Molecular Genetics and Genomics, 1987, 207, 486-491.	2.4	25
167	Alkyltriphenylphosphonium Turns Redox-Cycling Naphthoquinoneimidazoles into Potent Membrane Depolarizers Against <i>Mycobacteria</i>. SSRN Electronic Journal, 0, , .	0.4	0